BBOT logo

BRIDGEBIO ONCOLOGY THERAPEUT

BBOTNASDAQ
πŸ† #3367 by market capEarnings Nov 9US Equity
$303.07β–Ό $22.37 (βˆ’7.38%)
Simulated price
πŸ””
Track BBOT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 7.4%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$305M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
56
Weak
No chart data available for BBOT.

Trading Snapshot

Day Range
$301.85 – $308.82
52-Week Range
$3.89 – $14.87
Volume
$4.54B
Avg Volume
$3.47B
Shares Outstanding
80.1M
Next Earnings
Nov 7, 2026

Fundamentals Snapshot

Annual Revenue
$28M
Last Q Revenue
$7M
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-3.04
Dividend Yield
β€”
Dilution (1yr)
+436894.1%

Why Investors Own BBOT

  • βœ“High-growth profile β€” revenue up -4.0% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 69% gross margin and 11% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BBOT logo

BRIDGEBIO ONCOLOGY THERAPEUT

BBOT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$146Mβ–² +80.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$115Mβ–² +14890.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
80.0Mβ–² +436894.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$371Mβ–² +$369M YoY
StockOtter Β· stockotter.space

About BRIDGEBIO ONCOLOGY THERAPEUT

BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3KΞ±, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
56/100

Analyst Price Target

β“˜
Average Target
$382.27
β–² +26.1% Upside
High Target$459.03
Low Target$303.13
Based on 36 analysts

Latest News & Updates

πŸš€
CNBCΒ·2h ago

BRIDGEBIO ONCOLOGY THERAPEUT tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

πŸ›°οΈ
Barron’sΒ·5h ago

Analysts lift BBOT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatchΒ·1d ago

BRIDGEBIO ONCOLOGY THERAPEUT announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.